
Eurobio Introduces New Rapid Sequence Based Typing Test for HLA Testing Using Oxford Nanopore Long-Read Technology
Eurobio Scientific has unveiled its new product, NGS-Turbo®, developed by its subsidiary GenDx. NGS-Turbo is designed for HLA (Human Leukocyte Antigen) typing using sequencing devices from Oxford Nanopore Technologies and is intended for Research Use Only (RUO). NGS-Turbo is distinguished by its rapid turnaround time, delivering high-resolution HLA typing results in as little as three hours, from the collection of a blood sample to the final result. The product reflects GenDx’s commitment to pushing the boundaries of innovation in the field of HLA typing, providing advanced solutions for the transplantation community.
Most HLA antibody testing is done using multiplexed PCR tests that screen for the presence of antibody DNA markers in a patients blood. One Lambda, part of Thermo Fisher Scientific and BioRad Laboratories are leaders in this area. However, this process can be expensive and time consuming. Sequence based typing is becoming more common as a methodology to assess HLA antibody status for the donor and recipient, especially technologies that offer longer read capabilities. A study using PacBio’s long-read technology recently assessed the potential for sequencing to replace multiplexed PCR methods finding advantages of the technique. Oxford Nanopore is also known for its long-read technology.
Denis Fortier, CEO of Eurobio Scientific, emphasized that the new product is poised to expand their market share in HLA typing and potentially revolutionize the transplant market. By reducing the compatibility test to just three hours, NGS-Turbo opens up new possibilities for situations where existing technologies are too slow to test high-resolution compatibility. The launch of NGS-Turbo reaffirms Eurobio Scientific’s strong capacity for innovation in the field of life sciences and medical diagnostics.